Company: EDSA
Filing Date: 2025-07-25
Form Type: S-3
Source: 0001171843-25-004721
Chunk: 1

Company: Edesa Biotech, Inc.
Filing Date: 2025-07-25
Form: S-3
Chunk 1
---
old under the registrant’s Registration Statement on Form S-3 (File No. 333-266604) originally declared
effective on August 12, 2022 (the “Prior Registration Statement”). Pursuant to Rule 415(a)(5)(ii) under the Securities
Act, by filing this registration statement on Form S-3, the Company may issue and sell securities covered by the Prior Registration Statement
until the earlier of (i) the effective date of this registration statement and (ii) February 8, 2026, which is 180 days
after the third-year anniversary of the original effective date of the Prior Registration Statement. Pursuant to Rule 415(a)(6) under
the Securities Act, the offering of securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness
of this registration statement.

The information in this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold until the registration statement is effective. This prospectus is not an offer to sell these securities and does not solicit an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

<div align='center'>Subject to completion, dated July 25, 2025</div>

PROSPECTUS

<div align='center'>Edesa Biotech, Inc.

$150,000,000

Common Shares

Preferred Shares

Warrants

Debt Securities

Subscription Rights

Units</div>

We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common shares, (ii) our preferred shares, which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi) units. The debt securities may consist of debentures, notes or other types of debt. The debt securities, preferred shares, warrants and subscription rights may be convertible into, or exercisable or exchangeable for, common shares, preferred shares or other securities of ours. The units may consist of any combination of the securities listed above.

We may offer these securities in amounts, at prices and on terms determined at the time of offering. We may sell the securities directly to you, through agents we select, or through underwriters and dealers we select. If we use agents, underwriters or dealers to sell the